Sumitomo Dainippon Pharma, Poxel Ink $300M Diabetes Pact Post author:Sam Post published:October 29, 2017 Post category:BioPharma The two companies will jointly develop Imeglimin for the treatment of type 2 diabetes in Japan. Source: BioSpace You Might Also Like argenx Bags $231M in Upsized U.S. IPO December 13, 2017 Bay Area's Guardant Health Just Snagged $360 Million to Create Cancer Blood Tests May 10, 2017 Eli Lilly Quietly Works on Wearable Devices in Lab Established in 2015 November 21, 2017